Kerala Ayurveda has approved a preferential allotment of up to 7.2 lakh equity shares to its promoter group entity, Katra Holding Private Limited, at ₹190.37 per share.

Board outcome: loan conversion approved

The board meeting held on September 4, 2026, considered and approved the preferential issue of equity shares towards the conversion of an outstanding unsecured loan from Katra Holding Private Limited. The allotment involves 7,20,000 equity shares of face value ₹10 each, aggregating to ₹13.71 crore.

This transaction partially adjusts the existing unsecured loan of ₹26.41 crore held by the promoter group category lender. The issue price of ₹190.37 is not less than the floor price determined in accordance with Chapter V of the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018. The relevant date for determining the floor price was Friday, August 28, 2026.

Shareholding impact

The preferential allotment will increase Katra Holding Private Limited's stake in the company. Pre-issue, the entity held 6.3 lakh shares, representing 4.85% of the total shareholding. Post-allotment, its holding will rise to 13.5 lakh shares, or 9.84%.

34th AGM scheduled for September 28

The board also approved convening the 34th Annual General Meeting on Monday, September 28, 2026, at 11:00 am through Video Conferencing or Other Audio-Visual Means. The AGM will seek shareholder approval for the preferential issue, as required under SEBI regulations.

Trading window reopens

In compliance with SEBI insider trading regulations, the trading window for designated persons and their immediate relatives remains closed. It will reopen 48 hours after the announcement of the board meeting outcome. The disclosure was made pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Kerala Ayurveda Limited reported a consolidated net loss of ₹8.08 crore for the quarter ended June 30, 2026 (Q1FY26), widening significantly from a net loss of ₹2.03 crore in the corresponding period of FY25. Standalone results showed a net loss of ₹7.67 crore compared to a profit of ₹2.07 crore in Q1FY25, driven by rising operational costs and increased finance expenses. The Board of Directors approved these unaudited financial results on August 12, 2026, alongside the amalgamation of its wellness subsidiary and an employee stock option grant.

The company’s standalone revenue from operations fell to ₹22.53 crore in Q1FY26, down from ₹24.57 crore in Q4FY26 but up from ₹17.57 crore in Q1FY25. Total expenses rose to ₹31.84 crore from ₹24.99 crore year-on-year, primarily due to a surge in employee benefits expense to ₹13.18 crore and finance costs increasing to ₹2.81 crore. Consolidated revenue from operations stood at ₹33.19 crore, slightly lower than the ₹34.74 crore reported in the preceding quarter but up from ₹28.61 crore in Q1FY25.

Beyond financial results, the Board approved the Scheme of Amalgamation between Kerala Ayurveda Limited and its wholly-owned subsidiary, Ayurvedagram Heritage Wellness Centre Private Limited. The merger, subject to shareholder and National Company Law Tribunal approval, aims to streamline operations, reduce regulatory compliances, and integrate assets including intellectual property. The transaction does not fall under related-party transaction regulations as it involves a holding company and its wholly-owned subsidiary.

The Nomination and Remuneration Committee granted 64,875 Employee Stock Options under the Kerala Ayurveda Employee Restricted Stock Unit Plan, 2023. The options carry an exercise price of ₹10 per share and vest according to the scheme’s terms, exercisable within one year post-vesting. Additionally, the Board recommended the re-appointment of Non-Executive Director Ramesh Vangal at the ensuing Annual General Meeting on September 28, 2026.

What the Numbers Show

The divergence between standalone profitability trends highlights structural cost pressures within the parent entity. While consolidated revenues grew 16% year-on-year, the standalone segment swung from a profit to a significant loss, indicating that overheads and finance costs are outpacing top-line growth in the core Indian operations. The acquisition of the remaining 26% stake in Ayurvedagram during the period, executed via a share swap of 304,887 equity shares, has fully consolidated this subsidiary, potentially impacting future comparability as its wellness center revenues and margins blend directly into the group’s primary healthcare and pharmaceutical focus.